samedan logo
 
 
 
spacer
home > ebr > autumn 2009 > access to finance
PUBLICATIONS
European Biopharmaceutical Review

Access to Finance

A CONSTRAINED CAPITAL ENVIRONMENT

The financial crisis is affecting high-tech small and medium enterprises (SMEs), startups in particular, as they are confronted with three types of risk: technological risk, resulting from the explorative nature of R&D and production of high-tech goods; market risk, as a result of the uncertainty in the high-tech product market; and financial risk, as high-tech innovation usually requires huge investment. However, most high-tech startups lack long-term investment capability. The risks for biotech SMEs are concentrated at the sector and operational levels. Even before the financial crisis, funding for biotech SMEs was different from other industries, and the risks they face reflect unique challenges and circumstances. In this high-risk environment, investors have historically had to develop different metrics in valuing biotech companies. A specific characteristic of the biotech industry is the long and costly development process. While larger biotech firms already have products on the market, young and innovative biotech SMEs need significant funding to develop a product before generating significant potential for commercialisation, and this funding – through risk capital – has proved insufficient, especially in times of economic and financial crisis.

European biotech companies are facing a critical financial shortfall that could have profound consequences for the future of Europe’s knowledge-based economy in terms of both the drug development pipeline and job creation. Almost three-quarters of the UK’s 295 drug development SMEs, for example, are experiencing difficulties raising funds due to a closed IPO window, a huge reduction of available venture capital, and a significant increase in credit spreads due to the worldwide economic downturn. For this reason, a paper has been tabled, proposing five measures to overcome the financing problems that European biotech SMEs are facing as a result of the financial crisis, and to improve the situation of innovative drug developers (1).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dirk Carrez is an engineer in Chemistry and Agricultural Industries (Bioengineer) of Ghent University, and holds a PhD in Agricultural Sciences. Since September 2004, he has been Director of Industrial Biotechnology at EuropaBio (The European Association for BioIndustries), where he is coordinating activities in the area of industrial biotechnology and the ‘biobased economy’, as well as issues such as research and innovation, SMEs and access to finance. The positions he has held previously include Secretary-General of BelgoBiotech and Director of Innovation & Product Policy of Fedichem.
spacer
Dirk Carrez
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera launches UniSpray, its unidose system primarily for systemic-acting drug administration

Nemera has a proven track record in developing and manufacturing complex Ear Nose and Throat solutions. In line with clear growing market interest in unidose system coupled with promising advantages that nasal route could offer, Nemera is thrilled to extend its portfolio by launching its unidose system, UniSpray, for systemic-acting drug administration to face emergency and crisis.
More info >>

White Papers

Overcoming research challenges with Adaptive Trials

PCI Pharma Services

There has been cause for concern within the pharmaceutical industry over the last five years, regarding increasing research and development costs, combined with a fall in the number of new drugs brought to market. In an attempt to overcome this issue there has been a significant rise in the use of adaptive clinical trial designs, whilst saving time and money as well as facilitating more effective decision making. One of the biggest challenges that pharmaceutical companies have experienced has been delivering compliant clinical trials supplies across diverse patient populations in the relatively short timeframes that adaptive trial designs require, remaining focused on ensuring that patient compliance and product quality is in no way compromised. This demand has led to the launch of fast response services that support Research and Development in responding to changing dosing regimens mid-trial.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement